Gorlin Syndrome Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies – Mayne Pharma, PellePharm, Leo Pharma, Phyton Biotech, HedgePath Pharma, and Others

April 07 20:08 2022
Gorlin Syndrome Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight | Key Companies - Mayne Pharma, PellePharm, Leo Pharma, Phyton Biotech, HedgePath Pharma, and Others
Delveinsight Business Research LLP
DelveInsight’s “Gorlin Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Gorlin Syndrome Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Gorlin Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market. 

Gorlin Syndrome Market

Gorlin Syndrome: An Overview

Gorlin Syndrome, also known as Nevoid basal cell carcinoma (NBCCS), is an infrequent multisystemic disease that is inherited in an autosomal dominant way and shows a high level of penetrance and variable expressiveness. Nevoid basal cell carcinoma syndrome (NBCCS) is known to be a rare autosomal dominantly inherited entity that is characterized most strikingly by the development of cutaneous basal cell carcinomas from an early age, typically puberty, although in some cases, it may occur earlier in childhood. Mutations in the PTCH1 gene cause Gorlin syndrome. This gene provides instructions for making a protein called patched-1, which functions as a receptor.

Gorlin Syndrome Market Key Facts

  • According to the National Institute of Health (NIH), United States, Gorlin syndrome affects an estimated 1 in 31,000 people. While more than 1 million new cases of basal cell carcinoma are diagnosed each year in the United States, less than 1% of these skin cancers are related to Gorlin syndrome.

  • It has also been observed that the estimated prevalence of NBCCS has no observed sex predilection i.e., the male-to-female ratio is 1:1.

  • Cancer Research Organization (United Kingdom) suggests that Gorlin syndrome affects about 1 in 31,000 people. Between 70 and 80 out of every 100 people (70-80%) with Gorlin syndrome have someone else in their family with it, and have inherited a genetic mutation from one of their parents.

Gorlin Syndrome Market

Gorlin Syndrome market size is expected to increase during the forecast period owing to the launch of upcoming therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Gorlin Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Gorlin Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Gorlin Syndrome Epidemiology

The epidemiology section covers insights into the historical and current Gorlin Syndrome patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Gorlin Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gorlin Syndrome market or expected to get launched in the market during the study period. The analysis covers Gorlin Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Gorlin Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/gorlin-syndrome-market

Gorlin Syndrome Therapeutics Analysis

Worldwide some of the major pharma players are involved in developing therapies for the treatment and management of Gorlin Syndrome. The launch of emerging therapies is expected to transform the treatment landscape.

Some of the key companies in the Gorlin Syndrome Market include:

  • HedgePath Pharmaceuticals

  • Mayne Pharma 

  • PellePharm

  • Leo Pharma

  • Phyton Biotech

And many others

Gorlin Syndrome Therapies covered in the report include:

  • SUBA-Itraconazole

  • Patidegib

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/gorlin-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Gorlin Syndrome Competitive Intelligence Analysis

4. Gorlin Syndrome Market Overview at a Glance

5. Gorlin Syndrome Disease Background and Overview

6. Gorlin Syndrome Patient Journey

7. Gorlin Syndrome Epidemiology and Patient Population

8. Gorlin Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Gorlin Syndrome Unmet Needs

10. Key Endpoints of Gorlin Syndrome Treatment

11. Gorlin Syndrome Marketed Products

12. Gorlin Syndrome Emerging Therapies

13. Gorlin Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Gorlin Syndrome Market Outlook (7 major markets)

16. Gorlin Syndrome Access and Reimbursement Overview

17. KOL Views on the Gorlin Syndrome Market.

18. Gorlin Syndrome Market Drivers

19. Gorlin Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/gorlin-syndrome-market

Other Latest Reports By DelveInsight

Decompensated Cirrhosis Market

DelveInsight’s “Decompensated Cirrhosis Market” report delivers an in-depth understanding of the Decompensated Cirrhosis, historical and forecasted epidemiology as well as the Decompensated Cirrhosis market size, share, and trends in the 7MM.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/